Last reviewed · How we verify
TicoVac
At a glance
| Generic name | TicoVac |
|---|---|
| Sponsor | University of Surrey |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac (PHASE4)
- Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TicoVac CI brief — competitive landscape report
- TicoVac updates RSS · CI watch RSS
- University of Surrey portfolio CI